Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 2/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30642259 | 1.00 | BTK (0.46) | BTKKDM1AMAOBCTSKGAA | |
| SCHEMBL12528145 | 1.00 | BTK (0.46) | BTKKDM1AMAOBCTSKGAA | |
| SCHEMBL4778890 | 1.00 | BTK (0.46) | BTKKDM1AMAOBCTSKGAA | |
| SCHEMBL30772643 | 1.00 | BTK (0.46) | BTKKDM1AMAOBCTSKGAA | |
| SCHEMBL19898629 | 1.00 | BTK (0.46) | BTKKDM1AMAOBCTSKGAA | |
| SCHEMBL603315 | 1.00 | BTK (0.46) | BTKKDM1AMAOBCTSKGAA | |
| SCHEMBL12527248 | 0.88 | BTK (0.43) | BTKKDM1AMAOBCTSKGAA | |
| SCHEMBL9885693 | 0.88 | BTK (0.43) | BTKKDM1AMAOBCTSKGAA | |
| SCHEMBL12527395 | 0.88 | BTK (0.46) | BTKKDM1AMAOBCTSKGAA | |
| SCHEMBL22623131 | 0.87 | BTK (0.40) | BTKKDM1AMAOBCTSKGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3390384-B1 | QUINOLINE-3-CARBOXAMIDES AS H-PGDS INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2021-09-15 | — | — | EP | disclosed |
| US-20210238162-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-08-05 | — | — | US | disclosed |
| US-11020398-B2 | Amino-pyrrolopyrimidinone compounds and methods of use thereof | ARQULE, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20180055846-A1 | AMINO-PYRROLOPYRIMIDINONE COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. | 2018-03-01 | — | — | US | disclosed |
| WO-2017103851-A1 | QUINOLINE-3-CARBOXAMIDES AS H-PGDS INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2017-06-22 | — | — | WO | disclosed |
| US-8563714-B2 | Bridged spiro [2.4] heptane derivatives as ALX receptor and/or FPRL2 agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-10-22 | — | — | US | disclosed |
| EP-2417141-B1 | 2-HYDROXYETHYL-1H-QUINOLIN-2-ONE DERIVATIVES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY | ACTELION PHARMACEUTICALS LTD (CH) | 2013-10-16 | — | — | EP | disclosed |
| EP-2432760-B1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-07-17 | — | — | EP | disclosed |
| US-8415375-B2 | 2-hydroxyethyl-1H-quinolin-2-one derivatives and their azaisosteric analogues with antibacterial activity | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-04-09 | — | — | US | disclosed |
| US-8193179-B2 | 3-amino-6-(1-amino-ethyl)-tetrahydropyran derivatives | ACTELION PHARMACEUTICALS, LTD (CH) | 2012-06-05 | — | — | US | disclosed |
| EP-2167494-B1 | 3-AMINO-6-(1-AMINO-ETHYL)-TETRAHYDROPYRAN DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2011-08-17 | — | — | EP | disclosed |
| EP-2167494-B1 | 3-AMINO-6-(1-AMINO-ETHYL)-TETRAHYDROPYRAN DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2011-08-17 | — | — | EP | disclosed |
| US-7981886-B2 | Antibiotics derivatives | ACTELION PHARMACEUTICAL LTD. (CH) | 2011-07-19 | — | — | US | disclosed |
| US-20100179135-A1 | 3-AMINO-6-(1-AMINO-ETHYL)-TETRAHYDROPYRAN DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-07-15 | — | — | US | disclosed |
| US-20100179135-A1 | 3-AMINO-6-(1-AMINO-ETHYL)-TETRAHYDROPYRAN DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-07-15 | — | — | US | disclosed |
| US-20100179135-A1 | 3-AMINO-6-(1-AMINO-ETHYL)-TETRAHYDROPYRAN DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-07-15 | — | — | US | disclosed |
| WO-2008152603-A1 | 3-AMINO-6-(1-AMINO-ETHYL)-TETRAHYDROPYRAN DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-12-18 | — | — | WO | disclosed |
| EP-1996579-A2 | ANTIBIOTIC COMPOUNDS | Actelion Pharmaceuticals Ltd. (CH) | 2008-12-03 | — | — | EP | disclosed |
| US-20080280888-A1 | Antibiotics Derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-11-13 | — | — | US | disclosed |
| WO-2007105154-A2 | ANTIBIOTIC COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280888-A1 | Antibiotics Derivatives | NR4A1, NR2C2, NR4A3 | BTK 1795/4885KDM1A 1522/4885MAOB 1079/4885 |
| US-11020398-B2 | Amino-pyrrolopyrimidinone compounds and methods of use thereof | BTK, SYK, LCK | BTK 1/4885KDM1A 1485/4885MAOB 1170/4885 |
| US-20100179135-A1 | 3-AMINO-6-(1-AMINO-ETHYL)-TETRAHYDROPYRAN DERIVATIVES | ELANE, AAAS, DNPEP | BTK 3316/4885KDM1A 4344/4885MAOB 3079/4885 |
| US-20210238162-A1 | CHEMICAL COMPOUNDS | HPGDS, PTGS1, PTGIS | BTK 4035/4885KDM1A 880/4885MAOB 394/4885 |
| US-20180055846-A1 | AMINO-PYRROLOPYRIMIDINONE COMPOUNDS AND METHODS OF USE THEREOF | BTK, SYK, LCK | BTK 1/4885KDM1A 1485/4885MAOB 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.